🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 5 of 16

  1. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Diabetes Mellitus

    phase 3 mab completed

    1 trial

  2. VX-880

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetes Mellitus, Type 1

    phase 3 mab active

    1 trial

  3. VX-880 solution for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

    phase 3 small molecule active

    1 trial

  4. Vildagliptin

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  5. Vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  6. Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  7. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  8. Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalené tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets

    Istituto Gentili S.r.l.

    Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)

    phase 3 small molecule active

    1 trial

  9. aflibercept 8 mg PFS

    Regeneron UK Limited

    Diabetic Macular Edema (DME)

    phase 3 small molecule completed

    1 trial

  10. albiglutide + insulin glargine

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 mab completed

    1 trial

  11. biphasic insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  12. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  13. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, METFORMIN , INSULIN DEGLUDEC , INSULIN (HUMAN) , INSULIN GLARGINE , cagrilintide semaglutide, INSULIN DETEMIR , Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  14. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  15. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  16. cagrilintide, Placebo, cagrilintide, cagrilintide, cagrilintide

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  17. cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  18. candesartan

    Takeda

    Type 1 Diabetes

    phase 3 small molecule completed

    1 trial

  19. candesartan

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  20. candesartan cilexetil

    Takeda

    Type 1 Diabetes

    phase 3 small molecule completed

    1 trial

  21. evogliptin

    Dong Wang

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  22. exenatide once weekly

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  23. fluocinolone acetonide

    ANI PHARMACEUTICALS INC

    Diabetic Macular Edema

    phase 3 small molecule completed

    3 trials

  24. insulin degludec

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  25. linagliptine 5 mg

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  26. liraglutide

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  27. lixisenatide AVE0010

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  28. lorcaserin

    BRIGHT MINDS BIOSCIENCES INC.

    Obesity

    phase 3 small molecule terminated

    1 trial

  29. muraglitazar

    Bristol-Myers Squibb

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  30. ofloxacin

    ABEONA THERAPEUTICS INC.

    Diabetic Foot Ulcers

    phase 3 small molecule completed

    2 trials

  31. pioglitazone

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    1 trial

  32. placebo to match albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  33. rosiglitazone

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule terminated

    1 trial

  34. semaglutide

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    4 trials

  35. survodutide

    Boehringer Ingelheim

    Obesity

    phase 3 other active

    1 trial

  36. 0.59 mg fluocinolone acetonide intravitreal implant

    Bausch & Lomb Incorporated

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  37. 10mg DS-8500a tablet

    Daiichi Sankyo

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  38. 2HPβCD

    ZyVersa Therapeutics

    Diabetic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  39. 3-V Bioscience-2640

    Sagimet Biosciences

    Metabolic Syndrome

    phase 2 small molecule completed

    1 trial

  40. 4D-150 IVT

    4D Molecular Therapeutics

    Diabetic Macular Edema

    phase 2 mab active

    1 trial

  41. 5% Bisphosphocin Topical Gel

    Lakewood-Amedex Biotherapeutics

    Chronic Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial

  42. 5% Nu-3 gel

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infection

    phase 2 small molecule active

    1 trial

  43. 75 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  44. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  45. ALG-055009

    Aligos Therapeutics

    NASH

    phase 2 small molecule completed

    1 trial

  46. ALN-2232

    Alnylam Netherlands B.V.

    Obesity

    phase 2 small molecule active

    1 trial

  47. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  48. ALN-4324

    Alnylam Netherlands B.V.

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.